Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.
Oliver Wyman talks tackling medical waste at this year's StartUp Health Festival.
Oliver Wyman research highlights key treatment decision and prevalence of avoidable care.
The cost and toll of the opioid epidemic on the Medicaid population is alarming. Learn what states are doing to help address the problem.
Payers filed their ACA 2018 rates this week. Learn what happened, what it all means, and what comes next.
Understanding clinical variation is key to identifying inappropriate care; addressing inappropriate care is key to reducing costs and improving quality.
And we’re off! For those insurers who are still offering ACA plans, Oliver Wyman has developed a special series to help them optimize their performance in this complex market.
Insights into how Blue plans can navigate current market pressures and chart a successful path forward.
The results of a study of enrollees under the Affordable Care Act have potentially far-reaching implications for the Blues.
This is not your 2015 exclusive provider contracting. In 2016, these arrangements move beyond traditional narrow networks to deliver meaningful value-based components and differentiated consumer experiences.